Status of work in September
AOTMiT begins work on the Ministry of Health’s orders in September:
- Adcetris (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma
- Adcetris (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma
- Rystiggo (rozanolixumab) for the treatment of patients with generalized myasthenia gravis
- Hetronifly (serplulimab) in combination with carboplatin and etoposide for the first-line treatment of patients with DRC, cancer, and pleural mesothelioma
The listed order is available on the AOTMiT Public Information Bulletin.